Jazz Q3 2026: Revenue Beat and Guidance Raise Behind the Headline Loss
As seen on the 24/7 Wall St. homepage on November 2, 2026.
A $754 million acquired IPR&D charge from the Actio deal cut adjusted EPS by $11.03 a share, so the headline loss masks a quarter that beat. Revenue topped expectations and management raised full-year guidance.
Continue ReadingShow less
A $754 million in-process research-and-development charge tied to the Actio Biosciences acquisition swung adjusted EPS to -$3.88, missing expectations, while the underlying operating business stayed profitable.
Revenue of $1.243 billion rose 10.4% year over year and came in above consensus, led by Xywav, Zepzelca and the early Ziihera launch.
Sponsored
Management raised full-year 2026 revenue guidance and authorized a new $500 million share repurchase program in October 2026.
Near-term catalysts include JZP6979 patient data before year-end 2026, a Modeyso interim survival analysis in the first half of 2027 and an April 16, 2027 PDUFA date for an Epidiolex oral capsule.
Sources
Mentioned: JAZZ